does glp-1 cause gastroparesis Drug-Induced and Product Liability GLP-1 | Summary

In a clinical trial of patients with type 2 diabetes, weekly tirzepatide at 5, 10, or 15 mg for 40 weeks resulted in an 8.512.4% weight loss, compared to 6.7% with semaglutide at 1 mg/week [29]

While sulphonylureas potently promote insulin secretion in type-2 diabetic patients via inhibition of K ATP channel activity [[267], [268], [269], [270]], there is no clear evidence that sulphonylureas affect GLP-1 secretion in humans (as reviewed in [266])

Packed with antioxidants and health-supporting compounds

Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes

Adequate protein intake supports satiety hormones, including GLP-1